Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...
GlobalData on MSN22h
BioNTech signs agreement to acquire BiotheusBioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
in patients who failed therapy with drugs targeting vascular endothelial growth factor (VEGF). Sodhi and his colleagues ...
At about the same time, seminal observations implicating blood-vessel growth in intraocular disorders ... that a diffusible factor (named afterward 'factor X') could be responsible not only ...
Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...
To combat this, doctors prescribe medications that slow the growth of new blood vessels, called anti-VEGF (vascular ...
GlobalData on MSN7d
Minghui Pharmaceutical’s MHB039A shows promise in Phase I trial for solid tumoursMinghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with ...
Sandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadership ...
Age-related macular degeneration (ARMD) is the leading cause of severe vision loss in the developed world for people over 55 ...
Nov 2024 - Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax ...
BuzzHint on MSN3mon
Breakthrough in Male Pattern Baldness: Natural Sugar Sparks Hope for Hair RegrowthThe researchers appear to believe that 2dDR up-regulates vascular endothelial growth factor required for new hair growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback